Results 291 to 300 of about 92,434 (342)
Some of the next articles are maybe not open access.
Nature Reviews Rheumatology, 2018
The discovery of novel autoantigen systems related to idiopathic inflammatory myopathies (collectively referred to as myositis) in adults and children has had major implications for the diagnosis and management of this group of diseases across a wide range of medical specialties.
Neil J Mchugh, Sarah L Tansley
exaly +5 more sources
The discovery of novel autoantigen systems related to idiopathic inflammatory myopathies (collectively referred to as myositis) in adults and children has had major implications for the diagnosis and management of this group of diseases across a wide range of medical specialties.
Neil J Mchugh, Sarah L Tansley
exaly +5 more sources
Nature Reviews Rheumatology, 2018
The idiopathic inflammatory myopathies (IIMs; also known as myositis) are a heterogeneous group of disorders in which a common feature is chronic inflammation of skeletal muscle, leading to muscle weakness. Other organs are frequently affected in IIMs, such as the skin, joints, lungs, gastrointestinal tract and heart, contributing to morbidity and ...
Ingrid E Lundberg, Victoria P Werth
exaly +5 more sources
The idiopathic inflammatory myopathies (IIMs; also known as myositis) are a heterogeneous group of disorders in which a common feature is chronic inflammation of skeletal muscle, leading to muscle weakness. Other organs are frequently affected in IIMs, such as the skin, joints, lungs, gastrointestinal tract and heart, contributing to morbidity and ...
Ingrid E Lundberg, Victoria P Werth
exaly +5 more sources
Nature Reviews Rheumatology, 2018
As with the treatment of many immune-mediated diseases, managing myositis encompasses diverse factors, which present a challenge to the physician caring for these patients. The idiopathic inflammatory myopathies (IIMs, also known as myositis), are fundamentally heterogeneous; many contributory immunological perturbations are involved in the ...
Rohit Aggarwal
exaly +5 more sources
As with the treatment of many immune-mediated diseases, managing myositis encompasses diverse factors, which present a challenge to the physician caring for these patients. The idiopathic inflammatory myopathies (IIMs, also known as myositis), are fundamentally heterogeneous; many contributory immunological perturbations are involved in the ...
Rohit Aggarwal
exaly +5 more sources
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care
Nature Reviews Rheumatology, 2023 Juvenile idiopathic inflammatory myopathies (JIIMs) can differ from adult-onset myopathies in terms of the pathogenesis, autoantibody profile, disease phenotype and treatment response, but these differences need to be further defined.
Charalampia Papadopoulou +2 more
exaly +2 more sources
COVID-19 and Myositis: What We Know So Far
Current Rheumatology Reports, 2021 Myositis as a rare manifestation of COVID-19 is only recently being reported. This review examines the current literature on COVID-19-induced myositis focusing on etiopathogenesis, clinical presentations, diagnostic practices, and therapeutic challenges ...
Ahmad Saud, R Naveen, Rohit Aggarwal
exaly +2 more sources
Inclusion body myositis: clinical features and pathogenesis
Nature Reviews Rheumatology, 2019S. Greenberg
exaly +2 more sources
Annals of the Rheumatic Diseases, 2021
Objectives To investigate whether autoimmunity to transcriptional intermediary factor 1 (TIF1)γ, a ubiquitous nuclear autoantigen for myositis-specific autoantibodies detected in patients with dermatomyositis (DM) is pathogenetic for inflammatory ...
N. Okiyama +13 more
semanticscholar +1 more source
Objectives To investigate whether autoimmunity to transcriptional intermediary factor 1 (TIF1)γ, a ubiquitous nuclear autoantigen for myositis-specific autoantibodies detected in patients with dermatomyositis (DM) is pathogenetic for inflammatory ...
N. Okiyama +13 more
semanticscholar +1 more source
Risk factors and disease mechanisms in myositis
Nature Reviews Rheumatology, 2018 Frederick W Miller +2 more
exaly +2 more sources
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Neurology, 2018Objective To report the clinicopathologic features and outcome of myositis in patients treated with immune checkpoint inhibitors (ICIs) (irMyositis).
Mehdi Touat +19 more
semanticscholar +1 more source